QSAM Biosciences, Inc.
A408WA
Recommendation
--
Prev Close
Volume
--
Avg Vol (90D)
Market Cap
--
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)
--
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -57.37% | 0.67% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -58.62% | -6.36% | |||
| Operating Income | 58.62% | 6.36% | |||
| Income Before Tax | 58.44% | 5.95% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 58.44% | 5.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 58.44% | 5.95% | |||
| EBIT | 58.62% | 6.36% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -- | -- | |||
| Normalized Basic EPS | -- | -- | |||
| EPS Diluted | -- | -- | |||
| Normalized Diluted EPS | -- | -- | |||
| Average Basic Shares Outstanding | -- | -- | |||
| Average Diluted Shares Outstanding | -- | -- | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
